Boston Scientific Corporation (BVMF:B1SX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 427.05B -51.1% |
| Revenue (ttm) | 107.54B +17.4% |
| Net Income | 18.60B +75.4% |
| EPS | 12.47 +74.4% |
| Shares Out | n/a |
| PE Ratio | 22.96 |
| Forward PE | 16.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 1,701 |
| Open | 286.17 |
| Previous Close | 280.94 |
| Day's Range | 286.17 - 286.17 |
| 52-Week Range | 260.55 - 604.20 |
| Beta | 0.62 |
| RSI | 45.69 |
| Earnings Date | Apr 22, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Boston Scientific reports FRACTURE trial meets primary endpoint
Boston Scientific (BSX) announced results from the FRACTURE Investigational Device Exemption trial evaluating the use of the Seismiq 4CE Coronary Intravascular Lithotripsy Catheter to treat patients w...
Boston Scientific price target lowered to $75 from $78 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $75 from $78 and keeps an Outperform rating on the shares. The firm updated its model following its re-entry…
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...
3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
Three names are expected to have strong setups this week: Zeta Global ($ZETA), Boston Scientific ($BSX), and Summit Therapeutics ($SMMT). Each stock has its own catalyst, and analysts see room…
Here’s Why Boston Scientific’s Stock (BSX) Is Surging Today
The medical device maker is undertaking a big acquisition.
Boston Scientific price target lowered to $68 from $105 at BofA
BofA lowered the firm’s price target on Boston Scientific (BSX) to $68 from $105 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week…
Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup's heart-valve...
Boston Scientific enters $2B accelerated share repurchase agreement
Boston Scientific (BSX) announced that it has entered into an accelerated share repurchase agreement with JPMorgan Chase Bank, National Association for $2B of its common stock, as part of its…
Boston Scientific enters into $2 billion accelerated share repurchase agreement
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...
Boston Scientific Slides: Acquisition presentation
Boston Scientific has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Boston Scientific invests $1.5B for 34% equity stake in MiRus
Boston Scientific (BSX) announced it has invested $1.5B in return for an approximately 34% equity stake in MiRus, a privately-held company developing and commercializing proprietary biomaterials, impl...
Boston Scientific announces strategic investment in MiRus LLC
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientif...
Belo Sun to Commence Technical Studies on Volta Grande Gold Project
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Go...
Boston Scientific issues correction for ACCOLADE pacemakers, FDA says
The FDA is aware that Boston Scientific (BSX) has issued a letter to affected customers recommending all ACCOLADE pacemakers and CRT-Ps be corrected prior to continued use, the agency announced.
US FDA issues recall of Boston Scientific heart devices
Boston Scientific has issued an urgent recall to correct several heart devices after the U.S. Food and Drug Administration classified the action as its most serious recall, the regulator said on Thu...
Belo Sun Mining Corp. Begins Trading on OTCQX
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQX: BSXGF) is pleased to announce that effective today, its common shares have qualified to ...
Penumbra, Inc. Reports First Quarter 2026 Financial Results
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026.
Belo Sun Provides Update on Volta Grande Gold Project
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces an update on recent developments relating to its Volta Grande Gold ...
Boston Scientific Transcript: AGM 2026
The meeting reviewed strong 2025 financial results, strategic growth initiatives, and board updates. All directors were re-elected, and most company proposals passed, but neither proposal to lower the threshold for calling special shareholder meetings was approved. Litigation risks were addressed.
Procedure using Boston Scientific device tops medication for heart rhythm problem
We also report below on early data that poses a possible solution to a devastating pregnancy complication, and a potential breakthrough treatment for liver transplant patients.
Boston Scientific downgraded to Neutral from Outperform at Daiwa
Daiwa downgraded Boston Scientific (BSX) to Neutral from Outperform with a price target of $60, down from $83.
Boston Scientific price target lowered to $95 from $115 at Argus
Argus lowered the firm’s price target on Boston Scientific (BSX) to $95 from $115 but keeps a Buy rating on the shares after its Q1 results and guidance cut. The…
Boston Scientific announces data on Farapulse PFA Platform, Watchman LAAC
Boston Scientific (BSX) announced data supporting use of the company’s Farapulse Pulsed Field Ablation, PFA, Platform and Watchman Left Atrial Appendage Closure, LAAC, technologies. All data were pres...
Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions MARLBOROUGH, Mass. and CHICAGO, Apri...